eBook: HR Development within the Life Sciences Industry

XTalks

Disruption is very commonly witnessed in the life sciences industry hence human resources (HR) departments need to continuously come up with new talent strategies and recruitment practices to stay progressive. . What exactly does the future of HR look like as digital transformation escalates?

HR 87

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

The Pharma Data

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy. The study enrolled 222 patients with aggressive forms of HR+/HER2− MBC (i.e., months (HR=0.54; 95% CI: 0.36-0.79; p=.0007)

HR 61
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

BioTech 365

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast … Continue reading → Business Wire

HR 52

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

BioTech 365

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. … Continue reading → Business Wire

HR 52

Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study

The Pharma Data

months; hazard rate( HR) = 0.79;( 95 confidence interval( CI)0.65-0.96); p = 0.02). Trodelvy has not been approved by any nonsupervisory agency for the treatment of HR/ HER2- metastatic bone cancer. About HR/ HER2- bone Cancer. – 3.2

HR 74

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com

BioTech 365

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “HR+/HER2-VE Breast Cancer – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This HR+/HER2-VE Breast … Continue reading → Business Wire

HR 40

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services

BioTech 365

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services CALGARY, Alberta–(BUSINESS WIRE)–#albertadentist–With businesses everywhere struggling to keep their doors … Continue reading → Business Wire

HR 40

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

BioTech 365

HR 52

Capivasertib plus Faslodex significantly bettered progression-free survivalvs. Faslodex in CAPItello- 291 Phase III trial in advanced HR-positive bone cancer

The Pharma Data

roughly 70 of bone cancer tumours are considered HR-positive and HER2-low or negative.2 Endocrine curatives are extensively used for the treatment of HR-positive bone cancer, but numerous cases with advanced complaint develop resistance to 1st- line CDK4/ 6 impediments and estrogen receptor- targeting curatives, emphasizing the need for fresh options.3 Capivasertib plus Faslodex significantly bettered progression-free survivalvs.

HR 59

Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3

BioTech 365

Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3 Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R.

HR 52

^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo

BioTech 365

| Añadir a lista de seguimiento Biotech365 : ^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo BioMarketplace You want to propose your products or a Biotech … Continue reading → #BioMarketplace #BioMarketplace_ES #Biorad71,11 EURFecha de finalización: miércoles sep-16-2020 8:31:12 CESTCómpralo ya por sólo: 71,11 EUR¡Cómpralo ya! |

HR 40

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

BioTech 365

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer With the MONALEESA-2 final analysis, only … Continue reading → GlobeNewswire

HR 52

SET2,3 index can be prognostic in HR+ breast cancer, independent of recurrence score

Scienmag

Credit: SWOG/The Hope Foundation In an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer, a standard measure of gene expression known as the sensitivity-to-endocrine-therapy (SET2,3) index was found to have prognostic value that complemented the known prognostic value of the 21-gene breast recurrence score.

HR 70

Increasing the Business Value of Your HR Data: Integrate to Innovate

XTalks

HR organizations rely on access to employee data to address regulatory requirements, support modernization projects, manage talent, and address mergers and acquisitions. Why is having the right HR technology so important?

HR 75

Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer

The Pharma Data

Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

HR 52

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada

BioTech 365

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada OTTAWA, Ontario–(BUSINESS … Continue reading → Business Wire

HR 52

Can Your Employer Make You Get a Vaccine? A Conversation with an HR Consultant

BioSpace

We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic

HR 63

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

BioTech 365

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i New data underscore efficacy … Continue reading → GlobeNewswire

HR 40

Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020

The Pharma Data

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients whose tumours are PIK3CA positive.

HR 52

FIRST-LINE IBRANCE® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER

The Pharma Data

months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease.

HR 52

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

BioTech 365

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Results from pre-planned subgroup … Continue reading → GlobeNewswire

HR 40

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

BioTech 365

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast … Continue reading → Business Wire

HR 52

First new drug in years reduces recurrence in high risk HR+ early breast cancer

Scienmag

Data from latest research presented at the ESMO Virtual Congress 2020 Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study […].

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Pharma Mirror

The post Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval appeared first on Pharma Mirror Magazine. Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an ?-specific

HR 52

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

BioTech 365

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in … Continue reading → GlobeNewswire

HR 40

How Has COVID-19 Changed the Way We Work in the Life Sciences?

XTalks

Xtalks spoke with two HR professionals to find out how companies are handling the transition from a work-from-home policy to a hybrid or back-to-work model. News Blogs Career Insights Blogs Featured Pandemic Highlight COVID-19 Life Science Jobs HR

Life Science Careers: Leveraging AI in Talent Acquisition and Industry Expertise for Employers and Employees

XTalks

Therefore, the role of HR is critical at any organization. And on February 19, join An Insider’s Look: How Syneos Health is Shortening the Distance from Lab to Life in Clinical Trials for key industry HR insights for jobseekers. This includes hiring practices and HR management.

NTU launches two new programs to develop human resource talent with Institute for Human Resource Professionals

Scienmag

Credit: NTU Singapore Nanyang Technological University, Singapore (NTU Singapore) is collaborating with the Institute for Human Resource Professionals (IHRP) to launch two new MiniMasters™ programmes to develop talent in human resources (HR).

HR 76

Gilead's Trodelvy Data Leaves Some Questioning Clinical Advantage

BioSpace

Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting

HR 59

Saliva testing may allow early detection of human papillomavirus–driven head and neck cancers

Scienmag

Philadelphia, September 21, 2021 – Cancer causing high-risk human papillomaviruses (HR-HPV) are responsible for the rising incidence of HR-HPV–driven head and neck cancers (HNC), particularly oropharyngeal cancers (OPC, or throat cancers). Investigators have determined that HR-HPV DNA can be detected in saliva in most patients with HPV-driven OPC at the time of diagnosis.

HR 40

Camizestrant significantly bettered progression-free survivalvs. Faslodex in SERENA- 2 Phase II trial in advanced ER-positive bone cancer

The Pharma Data

roughly 70 of bone cancer tumours are considered HR-positive and HER2-low or negative.2 In addition to these results, the Company has also blazoned moment positive results from the CAPitello- 291 Phase III trial of capivasertib in HR-positive advanced bone cancer.

HR 68

20-year research breakthrough offers new hope for breast cancer patients

Scienmag

20-year research breakthrough offers new hope for high risk patients with HR+ breast cancer A new treatment for breast cancer patients with hormone receptor (HR+) early stage disease who are at a high risk of recurrence has been shown to reduce the risk by 25%, according to a study led by The Royal Marsden NHS […].

HR 54

Lilly Announces Details of donations at 2022 San Antonio bone Cancer Symposium

The Pharma Data

The Verzenio oral and bill donations will give streamlined clinical data from ongoing studies in early and advanced forms of hormone receptor-positive( HR), mortal epidermal growth factor receptor 2-negative( HER2-) bone cancer. An oral donation will give results from apre-planned overall survival( zilches) analysis from the Phase 3 monarchE study in HR, HER2-, knot-positive, high threat early bone cancer, including four- time efficacity issues.

HR 61

“Closest black hole” system found to contain no black hole

Scienmag

In 2020 a team led by European Southern Observatory (ESO) astronomers reported the closest black hole to Earth, located just 1000 light-years away in the HR 6819 system.

Leaders in Diversity, Equity, Inclusion and Accessibility to Be Recognized Through BioTalent Canada’s New Program

BioTech 365

Leaders in Diversity, Equity, Inclusion and Accessibility to Be Recognized Through BioTalent Canada’s New Program Leaders in Diversity, Equity, Inclusion and Accessibility to Be Recognized Through BioTalent Canada’s New Program OTTAWA, Ontario–(BUSINESS WIRE)–#HR–Today, BioTalent Canada launched the I.D.E.A.L

HR 52

Bio-economy Labour Market Information Now Available via New Online Portal

BioTech 365

HR 52

BioTalent Canada Awards 2022 Catalyst Award for Top New Hire

BioTech 365

BioTalent Canada Awards 2022 Catalyst Award for Top New Hire BioTalent Canada Awards 2022 Catalyst Award for Top New Hire OTTAWA, Ontario–(BUSINESS WIRE)–#HR–BioTalent Canada announced today that Erin Ward has won the 2022 Catalyst Award for Top New Hire.

HR 52

Enhertu significantly improved both progression-free and overall survival in DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer

The Pharma Data

Up to 55% of all patients with breast cancer have tumours with a HER2 IHC score of 1+, or 2+ in combination with a negative ISH test, a level of HER2 expression not currently eligible for HER2-targeted therapy.1,2 HER2-low expression occurs in both HR-positive and HR-negative disease.3.

HR 52

The power of similarities to accelerate antiviral development for COVID-19

Elsevier

In April 2020, I wrote a blog post entitled “ Exploiting similarities between SARS-CoV-2 and other viruses to accelerate vaccine and therapy development ,” where I described research areas leveraging genetic and phenotypic similarities between SARS-CoV- 2 and other known viruses.

BioTalent Canada Named as a “Best Workplace for Women” for 2022

BioTech 365

BioTalent Canada Named as a “Best Workplace for Women” for 2022 BioTalent Canada Named as a “Best Workplace for Women” for 2022 OTTAWA, Ontario–(BUSINESS WIRE)–#HR–BioTalent Canada is honoured to mark International Women’s Day by being recognized as a 2022 Best … Continue reading → Business Wire

HR 52

Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022

The Pharma Data

– Late-Breaking Presentation of Phase 3 TROPiCS-02 Study of Trodelvy ® Demonstrates Overall Survival Benefit in Pre-Treated HR+/HER2- Metastatic Breast Cancer –. About HR/ HER2- bone Cancer.

HR 73

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

The Pharma Data

1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease. 6 Currently chemotherapy remains the only treatment option for patients with HR-positive tumours following progression on endocrine (hormone) therapy.

HR 52

First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer

Scienmag

1) Credit: ESMO Lugano, Switzerland, 19 September 2021 – Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) […].